Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma.

Autor: Gil K; Department of Internal Medicine, University of Colorado School of Medicine, Aurora, USA., Abbasi S; Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City, USA., Mehta K; Department of Oncology, Kansas University Medical Center, Kansas City, USA., McClune B; Division of Hematology and Hematological Malignancies, University of Utah, Salt Lake City, USA., Sborov D; Division of Hematology and Hematological Malignancies, University of Utah, Salt Lake City, USA., Ahmed N; Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City, USA., Abdallah AO; Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City, USA., Ganguly S; Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City, USA., McGuirk J; Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City, USA., Shune L; Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Kansas City, USA., Mohyuddin GR; Division of Hematology and Hematological Malignancies, University of Utah, Salt Lake City, USA.
Jazyk: angličtina
Zdroj: Clinical hematology international [Clin Hematol Int] 2022 May 11; Vol. 4 (1-2), pp. 56-59. Date of Electronic Publication: 2022 May 11 (Print Publication: 2022).
DOI: 10.1007/s44228-022-00003-9
Abstrakt: Competing Interests: Conflict of interestNone of authors have any conflicts of interest to declare other than the following. DS: consulting for Janssen, SkylinDx, GlaxoSmithKline, Legend Biotech, Amgen and Celgene. SG: Daiichi Sankyo: Research Funding; Seattle Genetics: Speakers Bureau; Kite Pharma: Honoraria, Other: Advisory Board; Janssen: Honoraria. JM: Kite Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bellicum Pharmaceuticals: Research Funding; Astellas: Research Funding; Juno Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Fresenius Biotech: Research Funding; Gamida Cell: Research Funding; Pluristem Ltd: Research Funding; Articulate Science.
Databáze: MEDLINE
Externí odkaz: